Loading clinical trials...
Loading clinical trials...
A Single Dose-escalation Study to Evaluate the Safety and Efficacy of Allogeneic CAR-T Targeting CD19 (ThisCART19A) in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy
Conditions
Interventions
ThisCART19A
Fludarabine Pill
+2 more
Locations
1
China
Henan cancer hospital
Zhengzhou, Henan, China
Start Date
December 1, 2022
Primary Completion Date
February 1, 2025
Completion Date
August 1, 2025
Last Updated
December 7, 2022
Lead Sponsor
Henan Cancer Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions